Werbung ausblenden

News zu Oncodesign Precision Medicine Actions au Porteur EO -,34

OPM Announces Its 2024 Annual Results and Clinical Developments · Uhr · Business Wire
OPM Announces Poster Presentation on OPM-101, a RIPK2 Kinase Inhibitor, in Healthy Volunteers at UEG Week 2024 Conference · Uhr · Business Wire
OPM Announces Positive Results of Its Phase 1 in Healthy Volunteers with OPM-101: Strong Target Engagement With Excellent Safety Profile · Uhr · Business Wire
Oncodesign Precision Medicine (OPM) obtains ¬5.6 million in public funding for its DEMOCRITE program dedicated to the clinical development of OPM-101 · Uhr · Business Wire
OPM Announces Positive Interim Results of Its Phase 1 Study Evaluating OPM-101 in Healthy Volunteers · Uhr · Business Wire
Oncodesign Precision Medicine: Publication of the 2023 Financial Calendar · Uhr · Business Wire
OPM and Servier launch "FederAidd", an international virtual campus for open innovation to accelerate and make the Drug Discovery process more reliable thanks to Artificial Intelligence · Uhr · Business Wire